The Uncorrected Proofs
IMPORTANT TO KNOW
After the authors have received the letter of acceptance and have paid the publication fee, the uncorrected version of their article appears instantly on our web site. It provides DOI and dates of acceptance and online posting.
This „early bird“ version of the article has been made available at this early stage in order to provide the fastest access to the article and is not intended to be the final version. The manuscript will undergo copyediting, typesetting and review of the resulting proof before it is published in its final form. To be noted that changes to the article should not be requested at this stage; for the proofreading the authors will be contacted by the Editor. This first version of the article will be replaced by the final version as soon as the latter becomes available and moved from „Uncorrected proofs“ to the „Papers in press“.
Q. Su, B. Xu, Z. Tian and Z. Gong
Design and development of novel 1,2,3-triazole chalcone derivatives as potential anti-osteosarcoma agents via inhibition of PI3K/Akt/mTOR signaling pathway
S. M. Badr-Eldin, H. M. Aldawsari, U. A. Fahmy, O. A. A. Ahmed, N. A. Alhakamy, M. A. Alfaky, A. Sirwi, S. A. Hawsawi, A. H. Alzahrani, A. Y. Yaseen, M. Qassim and S. Kotta
Optimized D-α-tocopherol polyethylene glycol succinate/phospholipid self-assembled mixed micelles: A promising lipid-based nanoplatform for augmenting the antifungal activity of fluconazole